USPTO serial 79412149
MAXION
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 7, 2026
- Examiner
- MASON, JARED MICHAEL
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with MAXION?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ben Natter
Ben Natter Haug Partners, LLP745 Fifth AvenueNew York, NY 10151United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biochemicals, namely, polypeptides and engineered antibodies for scientific, laboratory or research purposes; polypeptides and engineered antibodies for use in the manufacture of pharmaceuticals and drugs; ion channel modulating and G-protein-coupled receptor modulating engineered antibodies for scientific, laboratory or research purposes; ion channel modulating and G-protein-coupled receptor modulating engineered antibodies for use in the manufacture of pharmaceuticals and drugs; engineered antibodies derived from mini-protein toxins for scientific, laboratory or research purposes; engineered antibodies derived from mini-protein toxins for use in the manufacture of pharmaceuticals and drugs | ACTIVE | — |
| 005 | Pharmaceuticals and pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel and G-protein-coupled receptor activity, in particular, preparations for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; drugs, namely, pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel and G-protein-coupled receptor activity, in particular, those for use in the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; antibodies for medical use; pharmaceuticals and drugs in the nature of pharmaceutical preparations incorporating antibodies, ion channel modulating antibodies, and G-protein-coupled receptor modulating antibodies or antibodies derived from mini-protein toxins for the treatment of diseases and conditions associated with dysregulation of ion channel and G-protein-coupled receptor activity, in particular, those for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; human vaccine preparations | ACTIVE | — |
| 042 | Scientific and technological services and research and design relating thereto, namely scientific research, analysis and testing in the fields of pharmaceuticals, biochemicals, polypeptides, antibodies, ion channel modulating antibodies, and G-protein-coupled receptor modulating antibodies and antibodies derived from mini-protein toxins; drug discovery and drug development services; conducting or providing research and development services for others in the field of antibodies; medical and scientific laboratory services relating to the production of antibodies, ion channel modulating and G-protein-coupled receptor modulating antibodies or antibodies derived from mini-protein toxins; antibody engineering; scientific research services relating to the discovery, preclinical and clinical development of therapeutic products; information, advisory and consultancy services in relation to all of the aforesaid | ACTIVE | — |
| 044 | Medical services; medical diagnostic testing, analysis and diagnostic services for the treatment of patients in the field of antibodies; medical services for the treatment of diseases through the use of antibodies, ion channel modulating antibodies, and G-protein-coupled receptor modulating antibodies or antibodies derived from mini-protein toxins, or pharmaceuticals, drugs and pharmaceutical preparations derived from the aforesaid; information, advisory and consultancy services in relation to all of the aforesaid | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Maxion Therapeutics Limited
- Other trademarks owned by Maxion Therapeutics Limited
- Other trademarks owned by Maxion Therapeutics Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named MAXION
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 1, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 13, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 13, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 7, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 28, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| May 11, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| May 11, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Apr 7, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 7, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 17, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 17, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 11, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 27, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 27, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 27, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 27, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 27, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 22, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 21, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 21, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 21, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 5, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 5, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 2, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 1, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 20, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 13, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 13, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 12, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |